Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Philip A Thompson

Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells

scientific article

Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients

scientific article published on 26 June 2019

Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia

scientific article published on 28 July 2016

Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide

scientific article

Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens

scientific article published on 20 July 2015

Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex

scientific article published on 27 January 2017

Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

scientific article published on 01 May 2019

Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma

scientific article

Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.

scientific article

Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib

scientific article

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

scientific article published on 27 November 2017

Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure

scientific article published on 6 April 2015

Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity

scientific article

Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets

scientific article published on 17 March 2022

Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments

scientific article published on 28 March 2019

STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage

scientific article published on 23 October 2019

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies

scientific article published on 17 April 2018

Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia

scientific article published on 20 February 2018

The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment

scientific article published on 20 December 2019

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab

scientific article published on 21 November 2017

The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience

scientific article published on 30 March 2015

The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype

scientific article published on 25 July 2019

Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia

scientific article published on 18 December 2014

β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia

scientific article published on 20 November 2015

Paulina is supported by:

About Paulina

Help